Filing Flows › Procept BioRobotics (PRCT) › Q2 2026 › vs Q1 2026
Procept BioRobotics (PRCT) Q2 2026 vs Q1 2026 (quarter over quarter)
Procept BioRobotics's revenue rose $11.4M (+14%) from $83.1M in Q1 2026 to $94.5M in Q2 2026.
Procept BioRobotics, Q2 2026: revenue $94.5M (+19% year over year), operating margin -29.0%, net loss $26.9M, operating cash flow −$19.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $94.5M | $83.1M | $11.4M | +14% |
| Other income, net | $623K | $925K | −$302K | -33% |
| Net loss | $26.9M | $31.6M | −$4.8M | -15% |
| Costs & expenses | $122M | $116M | $6.2M | +5% |
| Operating costs | $122M | $116M | $6.2M | +5% |
| Income tax | $94K | −$43K | $137K | — |
| Cost of revenue | $32.1M | $29.2M | $2.9M | +10% |
| Research & development | $20.1M | $21.5M | −$1.4M | -6% |
| SG&A | $69.7M | $65.1M | $4.6M | +7% |
| Operating cash sources | $35.8M | $52.9M | −$17.2M | -32% |
| Depreciation & amortization | $2.0M | $1.7M | $254K | +15% |
| Share-based compensation | $14.5M | $13.1M | $1.5M | +11% |
| Cash used in operations | $19.3M | $38.1M | −$18.9M | -50% |
| Net loss absorbed | $26.9M | $31.6M | −$4.8M | -15% |
| Working capital & other | $8.9M | $21.3M | −$12.4M | -58% |
Questions
How much did Procept BioRobotics's revenue grow quarter over quarter in Q2 2026?
Procept BioRobotics's revenue rose $11.4M (+14%) from $83.1M in Q1 2026 to $94.5M in Q2 2026.